Evaluate the effect of spermidine supplementation on lipid profile changes in individuals with overweight or obesity accompanied by hyperlipidemia. Analyze the impact of spermidine on metabolic parameters and assess the safety of spermidine supplementation, including liver and kidney function, gastrointestinal reactions, and other adverse effects.
Males or females aged 18 to 65 years.
BMI ≥ 24 kg/m², without severe chronic diseases.
Not currently using glucose-lowering or lipid-lowering medications.
Dyslipidemia defined as triglycerides ≥ 1.7 mmol/L or total cholesterol ≥ 5.2 mmol/L.
Diagnosis of acute or severe gastrointestinal disease
Concurrent participation in any other weight-loss therapy
Current use of hypoglycemic or lipid-lowering medications
Participation in any other clinical trial within one month prior to signing the informed consent form
Shanghai 10th People's Hospital
Lead sponsor